Does EVOLOCUMAB Cause Nephrolithiasis? 102 Reports in FDA Database
Lower Your Cholesterol — The Natural Way
The Oxidized Cholesterol Strategy: a science-backed plan for heart health.
According to the FDA Adverse Event Reporting System (FAERS), 102 reports of Nephrolithiasis have been filed in association with EVOLOCUMAB (REPATHA). This represents 0.1% of all adverse event reports for EVOLOCUMAB.
102
Reports of Nephrolithiasis with EVOLOCUMAB
0.1%
of all EVOLOCUMAB reports
1
Deaths
40
Hospitalizations
How Dangerous Is Nephrolithiasis From EVOLOCUMAB?
Of the 102 reports, 1 (1.0%) resulted in death, 40 (39.2%) required hospitalization, and 1 (1.0%) were considered life-threatening.
Is Nephrolithiasis Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for EVOLOCUMAB. However, 102 reports have been filed with the FAERS database.
What Other Side Effects Does EVOLOCUMAB Cause?
Device difficult to use (31,807)
Drug dose omission by device (23,957)
Wrong technique in product usage process (21,664)
Accidental exposure to product (16,160)
Injection site pain (9,988)
Product storage error (6,606)
Back pain (5,254)
Myalgia (5,061)
Drug dose omission (4,914)
Injection site bruising (4,409)
What Other Drugs Cause Nephrolithiasis?
ADALIMUMAB (2,416)
ETANERCEPT (1,292)
INFLIXIMAB (981)
METHOTREXATE (979)
ABATACEPT (788)
TOPIRAMATE (768)
CERTOLIZUMAB PEGOL (735)
RITUXIMAB (709)
TOFACITINIB (699)
SODIUM OXYBATE (698)
Which EVOLOCUMAB Alternatives Have Lower Nephrolithiasis Risk?
EVOLOCUMAB vs EXELON
EVOLOCUMAB vs EXEMESTANE
EVOLOCUMAB vs EXENATIDE
EVOLOCUMAB vs EXFORGE
EVOLOCUMAB vs EXJADE